N@N

BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2012 Financial Results on November 8, 2012

_{//health-fitness.news-articles.net/content/2012/ .. r-2012-financial-results-on-november-8-2012.html}
^{Published in Health and Fitness on Thursday, November 1st 2012 at 13:46 GMT by Market Wire}  

BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2012... -- LYNBROOK, N.Y., Nov. 1, 2012 /PRNewswire/ --

LYNBROOK, N.Y., Nov. 1, 2012 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: [ BSTC ]), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX^® in the U.S. and XIAPEX^® in Europe and Eurasia, announced today that it will host a conference call and live audio webcast at 4:30 p.m. EST on Thursday, November 8, 2012 to report its third quarter 2012 financial results and provide a corporate update.

In order to participate in the conference call, please dial 1-800-860-2442 (domestic) or 1-412-858-4600 (international). The live webcast can be accessed under "Calendar of Events" in the Investor Relations section of the Company's website at [ www.biospecifics.com ] or you may use the link: [ http://www.videonewswire.com/event.asp?id=90670 ].

A replay of the call will be available one hour after the end of the conference on November 8, 2012 until 9:00 a.m. EST on November 23, 2012. To access the replay, please dial 1-877-344-7529 (domestic) or 1-412-317-0088 (international) and reference the access code 10020975. The archived webcast will be available for 90 days in the Investor Relations section of BioSpecifics' website at [ www.biospecifics.com ].

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications. Currently, injectable collagenase is marketed as XIAFLEX® in the U.S. for the treatment of adult Dupuytren's contracture patients with a palpable cord by Auxilium Pharmaceuticals, Inc. (Auxilium) and is also in clinical development for the treatment of several additional promising indications. Auxilium has reported positive top-line results from two recently completed Phase III clinical trials for Peyronie's disease and is also testing XIAFLEX for frozen shoulder syndrome (adhesive capsulitis) and cellulite in Phase IIa and Phase Ib clinical trials, respectively. BioSpecifics is currently managing the clinical development of XIAFLEX for the treatment of human lipoma and canine lipoma, which are both in Phase II clinical trials.  Auxilium has entered into three strategic partnerships for development and commercialization outside the U.S. of injectable collagenase for Dupuytren's contracture and Peyronie's disease. Pfizer Inc. has rights in Europe and Eurasia and injectable collagenase is currently marketed as XIAPEX® for Dupuytren's contracture in select European countries. Asahi Kasei Pharma Corporation has rights in Japan and Actelion Pharmaceuticals Ltd. has rights in Canada, Australia, Brazil and Mexico. For more information, please visit [ www.biospecifics.com ].

SOURCE BioSpecifics Technologies Corp.